sponsored
PatientsVille.com Logo

PatientsVille

Ticlid Medical Research Studies

Up-to-date List of Ticlid Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Ticlid Medical Research Studies

Rank Status Study
1 Not yet recruiting Clopidogrel Resistance and Embolism in Carotid Artery Stenting
Condition: Carotid Stenosis
Interventions: Drug: Ticlopidine + Ginko biloba;   Drug: Clopidogrel
Outcome Measures: New ischemic lesion on diffusion-weighted imaging (DWI);   Number and Volume of new ischemic lesions on DWI;   Benign and malignant microembolic signals (MES) on transcranial Doppler (TCD);   Ischemic stroke or transient ischemic attack (TIA);   Change of clopidogrel resistance;   Pucture site hematoma;   Mycocardial infarction;   Death;   Hematological abnormalities
2 Recruiting Nobori Dual Antiplatelet Therapy as Appropriate Duration
Condition: Coronary Artery Disease
Interventions: Drug: Aspirin or thienopyridine;   Drug: Aspirin and thienopyridine
Outcome Measures: Net adverse clinical and cerebral event (NACCE);   All-cause death;   Non-fatal myocardial infarction;   Cerebrovascular events;   Major bleeding;   Rate of target lesion revascularization;   Minor bleeding
3 Not yet recruiting Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study)
Condition: Renal Artery Stenosis
Interventions: Drug: Optimal medical therapy;   Procedure: revascularization
Outcome Measures: Glomerular filtration rate in the ischemic kidney after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.;   Lowering blood pressure after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.;   Preserving overall renal function after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.;   Regression of damage in the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.
4 Unknown  Sufficient Treatment of Peripheral Intervention by Cilostazol
Condition: Arteriosclerosis Obliterans
Intervention: Drug: cilostazol
Outcome Measures: Angiographic restenosis rate;   Cardiovascular events
5 Not yet recruiting E-Selectin Nasal Instillation to Prevent Secondary Stroke
Conditions: Ischemic Attack, Transient;   Transient
Intervention: Drug: recombinant human E-selectin
Outcome Measures: To define the maximun tolerated dose of intranasal instillation of recombinant E-Selectin.;   To determine doses that generate Treg cells or induce immune deviation form TH1 to TH2 type response.
6 Unknown  Thrombelastogram in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery
Condition: Bleeding
Intervention:
Outcome Measures: Re-sternotomy d/t Bleeding;   Chest tube output during first 24 hours after the surgery
7 Recruiting RELIEF(A Randomized,Open labEled, muLticenter Trial for Safety and Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells Acute Myocardial inFarction)
Condition: Acute Myocardial Infarction
Intervention: Biological: Hearticellgram-AMI
Outcome Measure: LVEF by MRI
8 Recruiting Platelet Inhibition in Patients With Systolic Heart Failure
Condition: Systolic Heart Failure
Interventions: Drug: Prasugrel 10 mg daily x 2 weeks;   Drug: Clopidogrel 75 mg daily x 2 weeks
Outcome Measures: The change in platelet aggregation measured by the Accumetrics (VerifyNow P2Y12) assay between baseline and each antiplatelet medication;   The change in light transmission aggregometry (LTA)between baseline and each antiplatelet medication;   The change in platelet activation assay (VASP)between baseline and each antiplatelet medication
9 Not yet recruiting Optimal Anti-platelet Treatment for Patients With Clopidogrel Low Response
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Cilostazol
Outcome Measures: Inhibition of platelet aggregation (IPA);   Clinical efficacy
10 Recruiting Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
Condition: Coronary Heart Disease
Interventions: Drug: Clopidogrel 75mg;   Drug: Clopidogrel 150mg;   Drug: Aspirin 100mg;   Drug: Cilostazol 100mg
Outcome Measures: Major adverse cardiac and cerebrovascular events;   Secondary endpoint;   bleeding;   quality of life of patient
11 Not yet recruiting Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel
Condition: Thrombosis
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Stent thrombus;   Endothelial coverage of the stent struts assessed by optical coherence tomography;   Neointimal proliferation within the stent assessed by optical coherence tomography;   Stent malapposition assessed by optical coherence tomography;   Edge dissections assessed by optical coherence tomography
12 Recruiting Clopidogrel And Ticagrelor in Healthy Subjects
Condition: Pharmacodynamics of Antiplatelet Agent.
Interventions: Drug: Ticagrelor 90 mg;   Drug: Clopidogrel 600 mg
Outcome Measure: Platelet reactivity
13 Not yet recruiting Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
Condition: ST-Segment Elevation Myocardial Infarction
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measure: CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs)
14 Unknown  Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
Condition: Coronary Artery Disease
Interventions: Drug: Clopidogrel;   Drug: Placebo
Outcome Measures: Composite of death, myocardial infarction, stent thrombosis, stroke or TIMI major bleeding.;   The individual components of the primary endpoint
15 Recruiting Pharmacogenomics of Antiplatelet Response - I
Conditions: Platelet Aggregation;   Platelet Transcriptome;   Coronary Artery Disease
Interventions: Drug: Clopidogrel;   Drug: Aspirin
Outcome Measures: Difference in ADP-induced Platelet Aggregation;   Difference in Arachidonic Acid-induced Platelet Aggregation;   Difference in Collagen-induced Platelet Aggregation;   Changes in Platelet Transcriptome with Clopidogrel
16 Unknown  Blood Loss and Complications of Internal Fixation of Femoral Neck Fractures in Patients Treated With Clopidogrel
Conditions: Femoral Neck Fractures;   Pertrochanteric Fractures;   Antiaggregant Therapy
Interventions: Procedure: clopidogrel;   Procedure: no antiaggregant therapy
Outcome Measure: mortality 30 days, 1 year functional score 1 year blood loss at surgery blood transfusions during hospitalization wound complications
17 Recruiting PRAsugrel or clopIdogrel in Acute Coronary SyndromE Patients With CYP2C19 Polymorphism Before Percutaneous Coronary Intervention
Condition: Acute Coronary Syndromes
Interventions: Drug: Prasugrel;   Drug: Clopidogrel
Outcome Measures: HPR 1 day;   MACE;   Bleeding;   HPRs;   HPR by VASP at 24 hours;   HPR by VASP at 30 days
18 Recruiting Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Compare ticagrelor's versus clopidogrel's inhibition of the P2Y12 receptor as measured by the decrease in P2Y12 Reaction Units (PRU) using VerifyNow TM.;   Compare the decrease of P2Y12 Reaction Units (PRU) by VerifyNow TM from ticagrelor and clopidogrel.;   Compare the decrease in P2Y l2 Reaction Units (PRU) by VerifyNow™ from ticagrelor's and clopidogrel's morning dose on Day 7;   To evaluate and compare the pharmacodynamic effects, measured by the vasodilator-stimulated phosphoprotein (VASP) assay (platelet reactivity index [PRI]), in all subjects;   Assess and to compare the percentage of subjects with High on-treatment Platelet Reactivity (HPR) at all time points after randomized study treatment.
19 Recruiting Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
Conditions: Type-2 Diabetes Mellitus;   Coronary Artery Disease
Interventions: Drug: Ticagrelor + Aspirin;   Drug: Clopidogrel + Aspirin
Outcome Measures: Thrombus formation;   Platelet reactivity;   Vasodilator-Stimulated Phosphoprotein phosphorylation assay
20 Recruiting Effect of Clopidogrel on Allergen Challenge in Asthma
Condition: Asthma
Interventions: Drug: Clopidogrel;   Drug: Placebo
Outcome Measures: Change in sputum eosinophils following allergen challenge in the presence and absence of clopiodgorel;   Provoking concentration of methacholine inducing 20% fall in forced expiratory volume in 1 second;   Change in sputum tissue factor concentration following allergen challenge in the presence and absence of clopidogrel;   Change in sputum tissue factor inhibitor concentration following allergen challenge in the presence and absence of clopidogrel;   Change in sputum thrombin activatable finbrinolysis inhibitor concentration following allergen challenge in the presence and absence of clopidogrel;   Change in sputum P-selectin concentration following allergen challenge in the presence and absence of clopidogrel;   Change in peripheral blood eosinophil and platelet counts following allergen challenge in the presence and absence of clopidogrel;   Change in urine fibrin degradation products and leukotriene E4 following allergen challenge in the presence and absence of clopidogrel

These studies may lead to new treatments and are adding insight into Ticlid etiology and treatment.

A major focus of Ticlid research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Ticlid